MacroGenics Inc. (MGNX)

I maintain a tentative 'Buy' on MacroGenics, Inc., but acknowledge increased risk after the vobra duo failure and ongoing cash flow challenges. Lorigerlimab is now the lead pipeline candidate, with ke...

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fu...

MacroGenics (MGNX) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.84 per share a year ago.

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from ...

The heavy selling pressure might have exhausted for MacroGenics (MGNX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analyst...